Pravastatin Reduces the Incidence of Cardiac Events Among Patients With Myocardial Infarction
| Autor: | Akio Kimura, Ken Kanamasa, Tadahiko Yamamoto, Katsuhiko Katayama, Hiroki Furuta, Masaru Miyataka, Takahiro Hayashi, Toshihiko Takenaka, Kinji Ishikawa, Mitsugu Taniguchi |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Male
medicine.medical_specialty Myocardial Infarction Subgroup analysis Sudden cardiac death Internal medicine Epidemiology Secondary Prevention medicine Humans Myocardial infarction Aged Pravastatin Retrospective Studies business.industry Anticholesteremic Agents Incidence (epidemiology) Odds ratio Middle Aged medicine.disease Heart failure Cardiology Female Guideline Adherence Cardiology and Cardiovascular Medicine business Follow-Up Studies medicine.drug |
| Zdroj: | Japanese Heart Journal. 44:873-887 |
| ISSN: | 1348-673X 0021-4868 |
| DOI: | 10.1536/jhj.44.873 |
| Popis: | We retrospectively compared the incidence of cardiac events in myocardial infarction (MI) patients treated in our departments between 1990 and 1999 with pravastatin or without cholesterol-lowering agents. Our aim was to evaluate the efficacy of pravastatin in the secondary prevention of MI. Cardiac events -defined as fatal or nonfatal recurrent MI, sudden cardiac death, and death from congestive heart failure -occurred in 8 (2.2%) of 356 MI patients treated with pravastatin (17.1 cases/1,000 person • year) and in 39 (5.6%) of 700 MI patients not treated with cholesterol-lowering agents (54.3 cases/1,000 person • year), which represented a significant decline among those taking pravastatin (P < 0.05, odds ratio : 0.39, 95% CI: 0.18-0.84). Likewise, total mortality was significantly lower among patients treated with pravastatin (18 cases, 5.1% ; 38.4 cases/1,000 person • year vs 77 cases, 11.0% ; 107.2 cases/1,000 person • year, P < 0.01, odds ratio : 0.43, 95% CI: 0.25-0.73). Subgroup analysis revealed a significantly lower incidence of cardiac events in the pravastatin group for 6 of the items among 53 patient characteristics, and was lower but not significant for 45 items and was greater but not significant only for 2 items. Furthermore, multivariate analysis confirmed pravastatin to be a useful factor for preventing the occurrence of cardiac events in MI patients (P < 0.05, odds ratio: 0.44, 95% CI: 0.20-0.95), and Kaplan-Meier curves also showed pravastatin to significantly reduce the incidence of both cardiac events and total mortality. These findings are consistent with those previously reported by several large-scale clinical trials carried out in Western countries, and demonstrate that pravastatin is useful for secondary prevention of MI in Japanese patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|